false
0001196298
0001196298
2023-11-01
2023-11-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 1, 2023
NEPHROS,
INC.
(Exact
name of Registrant as Specified in its Charter)
Delaware |
|
001-32288 |
|
13-3971809 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
380 Lackawanna Place, South Orange, New Jersey 07079
(Address of principal executive offices, including ZIP code)
(201) 343-5202
(Registrant’s telephone number, including area code)
n/a
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
stock, $0.001 par value |
|
NEPH |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 |
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Nephros,
Inc. (the “Company”) appointed Judy Krandel as its Chief Financial Officer, effective November 1, 2023. Ms. Krandel was not
appointed pursuant to any arrangement or understanding with any person, and Ms. Krandel does not have any family relationships with any
directors or executive officers of the Company. Ms. Krandel has not had a direct or indirect material interest in any transaction with
the Company since January 1, 2021, nor is any such transaction currently proposed, that would be reportable under Item 404(a) of Regulation
S-K.
Prior
to joining the Company, Ms. Krandel, age 58, most recently served as Chief Financial Officer of Recruiter.com, a position she held from
June 2020 to June 2023. From November 2016 to December 2019, she served as Chief Financial Officer, and then Senior Business Development
Consultant for Paltalk, Inc. (f/k/a PeerStream, Inc.). From March 2012 to November 2016, Ms. Krandel was the Portfolio Manager for Juniper
Investment Company, a small-cap hedge fund. Ms. Krandel spent the earlier part of her career as an equity analyst and portfolio manager
focusing on small-cap public equities. She has previously sat on the board of directors of Lincoln First Bancorp, Snap Interactive and
Cynergistek in the banking, digital media and healthcare cybersecurity industries. She is a graduate of the Wharton School of Business
of the University of Pennsylvania with a degree in finance and the Booth School of Business of the University of Chicago with an M.B.A.
in finance and accounting.
Ms.
Krandel’s employment with the Company is subject to the terms of a letter agreement dated July 28, 2023 (the “Employment
Agreement”). In accordance with the Employment Agreement, Ms. Krandel will receive an initial base salary of $140,000 and will
be eligible for an annual performance bonus targeted at 25% of her annualized base salary, based primarily on Company performance and
other performance objectives established by the Board of Directors. In addition, pursuant to the Employment Agreement, Ms. Krandel received
a 10-year stock option to purchase an aggregate of 122,524 shares of the Company’s common stock as an inducement grant outside
the Company’s 2015 Equity Incentive Plan pursuant to Nasdaq Listing Rule 5635(c)(4) (the “Inducement Award”), which
option is exercisable at a price per share equal to $1.71, the closing price of the Company’s common stock on November 1, 2023.
Ms. Krandel’s right to purchase the shares will vest and become exercisable, subject to her continued employment, as to 25% of
the shares on the first anniversary of the grant date, and the remaining 75% of the shares subject to the option will thereafter vest
and become exercisable in twelve approximately equal quarterly installments.
The
foregoing summaries are qualified in their entirety by reference to the full text of the Employment Agreement and the Inducement Award,
copies of which will be filed with the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.
On
November 1, 2023, in connection with Ms. Krandel’s appointment as Chief Financial Officer, Andrew Astor resigned as the Company’s
Chief Financial Officer. The Company and Mr. Astor expect that he will continue his employment with the Company through approximately
December 31, 2023, during which time he will devote his time assisting Ms. Krandel in the transition.
A
copy of the press release announcing these executive changes is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item
9.01. |
Financial
Statements and Exhibits. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Nephros,
Inc. |
|
|
|
Dated:
November 6, 2023 |
By: |
/s/
Robert Banks |
|
|
Robert
Banks |
|
|
Chief
Executive Officer |
Exhibit 99.1
|
Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Call: 201 343 5202
nephros.com |
Nephros
Hires Judy Krandel as Chief Financial Officer
SOUTH
ORANGE, NJ, November 1, 2023 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions
to the medical and commercial markets, announced the appointment of Judy Krandel as Chief Financial Officer (CFO), effective today. In
this role, Ms. Krandel will be responsible for directing the company’s finances and working closely with the Chief Executive Officer
(CEO) and Board of Directors to develop and execute Nephros’s long-term strategy.
Ms.
Krandel joins the company with an impressive track record in financial leadership and strategic planning. She brings more than 20 years
of experience in asset management, investment, operations, financial reporting and oversight, as well as formal accounting expertise.
“We
are thrilled to welcome Judy to our team. She has an extensive history leading companies large and small to financial excellence as an
officer, a director, and an investor. I am confident in Judy’s ability to lead and oversee our financial operations.” said
Robert Banks, President and Chief Executive Officer.
Retiring
Chief Financial Officer Andy Astor commented, “With her background as both an investor and an executive, Judy is a superb choice
for Nephros. I am delighted to welcome her as my successor, and I believe she will effectively lead Nephros to continued growth and prosperity.”
Regarding
her new role, Ms. Krandel shared, “I am honored to come aboard at this exciting time, as Nephros enjoys positive cash flows and
growing revenue momentum. I look forward to being a part of the Nephros team and contributing to the shared success of the entire organization,
while helping to further the company mission of better water for all.” She continued, “Having tackled some of the most complex
financial, regulatory, and governance issues for the companies with which I have been involved, I am well-positioned to add significant
value for investors and stakeholders, and drive effective financial strategies.”
Prior
to joining Nephros, Ms. Krandel served as the Chief Financial Officer of Recruiter.com, where she worked closely with the CEO to leverage
AI and new technology to drive company growth while also building public market capitalization and enterprise value. Additionally, Ms.
Krandel was responsible for developing strategies for capital allocation, internal growth, and M&A while at Paltalk, Inc.
Ms.
Krandel holds a Bachelor of Science in Finance from the Wharton School and a Master of Business Administration from the University of
Chicago Booth School of Business. In addition to previous roles as Chief Financial Officer for two other publicly traded companies, Ms.
Krandel has been simultaneously active in multiple corporate and advisory boards.
Inducement
Stock Option Grant
Nephros
has approved the issuance of an inducement grant to Ms. Krandel, effective upon the commencement of her appointment as Chief Financial
Officer, consisting of a 10-year non-qualified stock option to purchase 122,524 shares of the Company’s common stock. The grant
was unanimously approved by the Company’s board of directors, including all of its independent directors and was a material inducement
to Ms. Krandel’s acceptance of employment with Nephros in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of her
employment compensation. The stock option will be equal to the closing sale price of the Company’s common stock as of the close
of regular trading today. The inducement grant will vest over a four-year period, with 25% of the shares vesting on November 1, 2024,
and the remaining shares thereafter vesting in 12 equal quarterly installments, subject to her continued employment with Nephros through
the applicable vesting dates. The inducement grant is subject to the terms and conditions of a stand-alone stock option agreement entered
into outside of the Company’s 2015 Equity Incentive Plan.
|
Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Call: 201 343 5202
nephros.com |
About
Nephros
Nephros
is committed to improving the human relationship with water through leading, accessible technology. We provide innovative water filtration
products and services, along with water-quality education, as part of an integrated approach to water safety. Nephros goods serve the
needs of customers within the healthcare and commercial markets, offering both proactive and emergency solutions for water management.
For
more information about Nephros, please visit nephros.com.
Forward-Looking
Statements
This
release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding
Nephros’ expected future revenue, gross margins, cash flows and expectations on achieving and maintaining positive cash flow and
profitability, including the timing thereof, and other future financial performance, and other statements that are not historical facts,
including statements that may be accompanied by the words “intends,” “may,” “will,” “plans,”
“expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those
described in these forward-looking statements due to certain factors, including inflationary factors and general economic conditions,
changes in business and competitive conditions, the availability of capital when needed, dependence on third-party manufacturers, distributors
and researchers, and regulatory reforms. These and other risks and uncertainties are detailed in Nephros’ reports filed with the
U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2022, which it may
update in Part II, Item 1A – Risk Factors in its Quarterly Reports on Form 10-Q that it has filed or will file hereafter. Nephros
does not undertake any responsibility to update the forward-looking statements in this release.
Investor
Relations Contacts:
Kirin
Smith, President
PCG
Advisory, Inc.
(646)
823-8656
ksmith@pcgadvisory.com
Robert
Banks, CEO
Nephros,
Inc.
(201)
343-5202
robert.banks@nephros.com
Judy
Krandel, CFO
Nephros,
Inc.
(201)
343-5202
judy.krandel@nephros.com
v3.23.3
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Nephros (NASDAQ:NEPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nephros (NASDAQ:NEPH)
Historical Stock Chart
From Apr 2023 to Apr 2024